News Content
UPS' Marken scores top marks in temp-control healthcare survey
A HEALTHCARE industry survey has shown that the world's largest package delivery company UPS its specialist pharmaceutical supply chain arm, Marken have been recognised as top provider of temperature data collection and management services for clinical trial materials.
New York-based Nice Insight's 2017 Clinical Supply Chain Logistics Survey questioned 320 large and midsize healthcare organisations in North America, Europe and Asia.
UPS/Marken consistently scored highest across a range of technical, operational and service capabilities.
UPS president of healthcare logistics strategy, Geoff Light, commented: "Improved health outcomes through sophisticated drugs and vaccines start with successful trials, and optimised logistics is an integral component of medical research and development."
The logistics company announced an expansion of its clinical trial capabilities in 2016 followed, in December, by its acquisition of Marken which collects and ships drug products, clinical trial materials and biological samples.
Marken is described as the only patient-centric supply chain organisation dedicated to the pharmaceutical and life sciences industries, offering direct-to-patient biological sample shipment services through a GMP-compliant network and hubs in 45 locations worldwide.
Said Marken CEO Wes Wheeler: "The explosive growth of cell and gene therapies is a good example of clinical research that requires a streamlined supply chain powered by a team experienced in logistics solutions for complex therapies."
New York-based Nice Insight's 2017 Clinical Supply Chain Logistics Survey questioned 320 large and midsize healthcare organisations in North America, Europe and Asia.
UPS/Marken consistently scored highest across a range of technical, operational and service capabilities.
UPS president of healthcare logistics strategy, Geoff Light, commented: "Improved health outcomes through sophisticated drugs and vaccines start with successful trials, and optimised logistics is an integral component of medical research and development."
The logistics company announced an expansion of its clinical trial capabilities in 2016 followed, in December, by its acquisition of Marken which collects and ships drug products, clinical trial materials and biological samples.
Marken is described as the only patient-centric supply chain organisation dedicated to the pharmaceutical and life sciences industries, offering direct-to-patient biological sample shipment services through a GMP-compliant network and hubs in 45 locations worldwide.
Said Marken CEO Wes Wheeler: "The explosive growth of cell and gene therapies is a good example of clinical research that requires a streamlined supply chain powered by a team experienced in logistics solutions for complex therapies."
Latest News
- For the first time, tianjin Port realized the whole process of dock operati...
- From January to August, piracy incidents in Asia increased by 38%!The situa...
- Quasi-conference TSA closes as role redundant in mega merger world
- Singapore says TPP, born again as CPTPP, is now headed for adoption
- Antwerp posts 5th record year with boxes up 4.3pc to 10 million TEU
- Savannah lifts record 4 million TEU in '17 as it deepens port
